Although the EGFR ex19del/C797S and L858R/C797S double mutations are sensitive to first- and second-generation TKIs, and NSCLC patients with trans mutations of ex19del/T790M/C797S and L858R/T790M/C797S can be treated with osimertinib combined with first-generation TKIs, the approved EGFR-TKIs still failed to address the resistance caused by the EGFR L858R/T790M/cis-C797S mutations (Figure 6). This evidence concerns the gene EGFR and non-small cell lung carcinoma.